IN8bio Inc. Common Stock

IN8bio Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200 a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100 an allogeneic product candidate which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400 which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300 INB-410 and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics Inc. and changed its name to IN8bio Inc. in August 2020. IN8bio Inc. was incorporated in 2016 and is headquartered in New York New York.